Clinical Trials Browser

Terminated × Cholangiocarcinoma × pembrolizumab × Clear all

Bile Duct Neoplasms, Neoplasm Metastasis, Cholangiocarcinoma

NCT05194072 2026-01-09

A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors

BreastGastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Adenoid Cystic, Fallopian Tube Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT05220722 2025-10-23

Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors

Phase 1/2 Terminated

23 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Cholangiocarcinoma

NCT02982720 2022-02-16

Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron

Phase 2 Terminated

4 enrolled 9 charts

Gastrointestinal

Cholangiocarcinoma

NCT02757391 2020-10-30

CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors

Phase 1 Terminated

1 enrolled

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Clinical Trials

MAST

A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors

Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors

Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron

CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors